
Feb 2 (Reuters) -
SANEGENEBIO ANNOUNCES RNAI GLOBAL LICENSING COLLABORATION WITH GENENTECH
SANEGENEBIO-WILL RECEIVE UPFRONT PAYMENT OF $200 MILLION, WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT, COMMERCIALIZATION MILESTONE PAYMENTS OF UP TO $1.5 BILLION
SANEGENEBIO - GENENTECH WILL BE RESPONSIBLE FOR SUBSEQUENT CLINICAL DEVELOPMENT AND COMMERCIALIZATION GLOBALLY